KCT0001617进行中（未招募）未知
A Phase 1 Randomised, Open Label, Dose-Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous CT-P27 with or without Oseltamivir in Healthy Subjects
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- Celltrion
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •Healthy Male & Female volunteers
排除标准
- •1. Subject has a medical condition of diseases including endocrine, cardiovascular, infection, cancer, or renal, neurological, and haematological disease.
- •2. History or presence of regular alcohol consumption
- •3. Subject in pregnancy or breastfeeding
- •4. Veins unsuitable for infusion and/or repeat venepuncture
- •5. Vulnerable subject
研究者
相似试验
已完成
不适用
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumoursoncologysolid tumors10027655NL-OMON47320Taiho Oncology Inc.40
已完成
1 期
Intramuscular inactivated rabies vector platform Corona Virus Vaccine (rDNA-BBV151)CTRI/2021/08/035425Bharat Biotech International Limited150
未知
1 期
A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast CancerJPRN-jRCT2080220921AstraZeneca
未知
1 期
A Phase 1, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors 1 and 2, in Japanese Subjects With Advanced Solid Tumours Refractory to Standard Therapy or for Which No Standard Therapy ExistsJPRN-jRCT2080221544AstraZeneca
已完成
1 期
A first-in-man clinical trial to evaluate the safety and immunogenicity of different doses of a malaria Vaccine (JAIVAC-1) in healthy Indian Male Subjects between 18 to 45 years of ageCTRI/2010/091/000301International Center for Genetic Engineering and Biotechnology MVDP45